• Zhihong Zhu, Yue Zhuo, Haitao Jin, Boyu Wu, and Zhijie Li.
• Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
• Medicine (Baltimore). 2021 Sep 17; 100 (37): e27215.

BackgroundNeurogenic bladder (NB), a refractory disease, is characterized by voiding dysfunction of bladder and/or urethra, and spinal cord injury (SCI) is a common cause. Chinese medicine therapies have been applied extensively in the treatment of NB, especially in China, and the results are promising but varying. Thus, the aim of this work is to assess the efficacy and safety of various Chinese medicine therapies for NB after SCI.MethodsA retrieval will be performed in 8 online databases (the Cochrane Library, Web of Science, PubMed, EMBASE Database, China Biological Medicine Database, Chinese Scientific Journals Database, Wan Fang databases, and China National Knowledge Infrastructure) from their inception throughout June 2021. Only randomized controlled trials of testing Chinese medicine therapies for NB after SCI will be enrolled. The outcome indicators measured will be overall response rate, urodynamic tests, clinical assessment, and safety assessments. The methodological quality of this Bayesian-based network meta-analysis will be conducted with the "Risk of Bias" tool. Stata14.0 and WinBUGS 1.4.3 will be used to analyze the data. Furthermore, the assessment of heterogeneity, inconsistency, subgroup, sensitivity, and publication bias will also be taken into consideration with the help of Cochrane Collaboration's tool.ResultsThe findings of this study will be submitted to a peer-reviewed journal for publication.ConclusionThis work will furnish evidence-based recommendations to figure out the optimal Chinese medicine therapy or their combinations for NB induced by SCI, and in turn contribute to further research and public health.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

31 keywords...

hide…